NASDAQ:CRSPCrispr Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Crispr Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $66.59 +2.01 (+3.11 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$62.55Now: $66.59▼$67.1850-Day Range$45.75MA: $56.52▼$69.9452-Week Range$32.30Now: $66.59▼$74.00Volume617,589 shsAverage Volume1.02 million shsMarket Capitalization$4.06 billionP/E Ratio88.79Dividend YieldN/ABeta2.34 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; CTX120, a CAR-T cell product candidate for the treatment of multiple myeloma; CTX130 for the treatment of solid tumors and hematologic malignancies; programs to treat Hurler Syndrome and severe combined immunodeficiency disease, as well as glycogen storage disease Ia; and programs targeting diseases, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreements with Vertex Pharmaceuticals, Incorporated and Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use various therapeutics; and StrideBio LLC to develop adeno-associated viral capsids. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing, developing, and commercializing gene-edited allogeneic stem cell therapies for the treatment of diabetes; and ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingCrispr Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 12 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.42, Crispr Therapeutics has a potential upside of 11.8% from its current price of $66.59.Amount of Analyst CoverageCrispr Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesCrispr Therapeutics has received 339 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCrispr Therapeutics has received 328 “underperform” votes. (Add your “underperform” vote.)Community SentimentCrispr Therapeutics has received 50.82% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Crispr Therapeutics and other stocks. Vote “Outperform” if you believe CRSP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRSP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCrispr Therapeutics does not currently pay a dividend.Dividend GrowthCrispr Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crispr Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,458,039.00 in company stock.Percentage Held by InsidersOnly 17.10% of the stock of Crispr Therapeutics is held by insiders.Percentage Held by Institutions57.97% of the stock of Crispr Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Crispr Therapeutics are expected to decrease in the coming year, from ($4.51) to ($5.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crispr Therapeutics is 88.79, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Crispr Therapeutics is 88.79, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.40.Price to Book Value per Share RatioCrispr Therapeutics has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.37 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRSP Previous Symbol CUSIPN/A CIK1674416 Webwww.crisprtx.com Phone41-41-561-3277Debt Debt-to-Equity RatioN/A Current Ratio16.87 Quick Ratio16.87Price-To-Earnings Trailing P/E Ratio88.79 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$289.59 million Price / Sales14.03 Cash Flow$1.34 per share Price / Cash Flow49.79 Book Value$17.02 per share Price / Book3.91Profitability EPS (Most Recent Fiscal Year)$1.17 Net Income$66.86 million Net Margins15.73% Return on Equity6.54% Return on Assets5.54%Miscellaneous Employees188 Outstanding Shares61,018,000Market Cap$4.06 billion Next Earnings Date8/3/2020 (Estimated) OptionableOptionable NASDAQ:CRSP Rates by TradingView Receive CRSP News and Ratings via Email Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Crispr Therapeutics (NASDAQ:CRSP) Frequently Asked Questions How has Crispr Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Crispr Therapeutics' stock was trading at $43.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRSP shares have increased by 53.9% and is now trading at $66.59. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Crispr Therapeutics? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crispr Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crispr Therapeutics. When is Crispr Therapeutics' next earnings date? Crispr Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Crispr Therapeutics. How were Crispr Therapeutics' earnings last quarter? Crispr Therapeutics AG (NASDAQ:CRSP) posted its earnings results on Tuesday, April, 28th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.05) by $0.10. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $3.04 million. Crispr Therapeutics had a net margin of 15.73% and a return on equity of 6.54%. The business's revenue for the quarter was down 52.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.93) EPS. View Crispr Therapeutics' earnings history. What price target have analysts set for CRSP? 15 equities research analysts have issued 1 year price objectives for Crispr Therapeutics' stock. Their forecasts range from $31.00 to $104.00. On average, they expect Crispr Therapeutics' share price to reach $74.42 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price. View analysts' price targets for Crispr Therapeutics. Has Crispr Therapeutics been receiving favorable news coverage? Media stories about CRSP stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crispr Therapeutics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutCrispr Therapeutics. Are investors shorting Crispr Therapeutics? Crispr Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,020,000 shares, an increase of 11.7% from the April 30th total of 3,600,000 shares. Based on an average daily volume of 1,000,000 shares, the short-interest ratio is presently 4.0 days. Approximately 8.5% of the shares of the stock are short sold. View Crispr Therapeutics' Current Options Chain. Who are some of Crispr Therapeutics' key competitors? Some companies that are related to Crispr Therapeutics include Neurocrine Biosciences (NBIX), BioNTech (BNTX), BIO-TECHNE (TECH), Qiagen (QGEN), argenx (ARGX), Repligen (RGEN), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), Momenta Pharmaceuticals (MNTA) and bluebird bio (BLUE). View all competitors. What other stocks do shareholders of Crispr Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crispr Therapeutics investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Intellia Therapeutics (NTLA), Canopy Growth (CGC), Square (SQ), Vertex Pharmaceuticals (VRTX) and Intel (INTC). Who are Crispr Therapeutics' key executives? Crispr Therapeutics' management team includes the following people: Dr. Rodger Novak, Founder, Chairman & Pres (Age 52)Dr. Samarth Kulkarni, CEO & Director (Age 40)Mr. Michael John Tomsicek, Chief Financial Officer (Age 53)Dr. Tony W. Ho, Head of R&D and Exec. VPDr. N. Anthony Coles Jr., Sr. Advisor (Age 59) When did Crispr Therapeutics IPO? (CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager. What is Crispr Therapeutics' stock symbol? Crispr Therapeutics trades on the NASDAQ under the ticker symbol "CRSP." Who are Crispr Therapeutics' major shareholders? Crispr Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Nikko Asset Management Americas Inc. (6.17%), Federated Hermes Inc. (1.77%), Morgan Stanley (1.40%), Morgan Stanley (1.40%), Wellington Management Group LLP (1.16%) and Cormorant Asset Management LP (1.03%). Company insiders that own Crispr Therapeutics stock include Kurt Von Emster, Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Vertex Pharmaceuticals (Europe. View institutional ownership trends for Crispr Therapeutics. Which institutional investors are selling Crispr Therapeutics stock? CRSP stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Two Sigma Investments LP, Orbimed Advisors LLC, Federated Hermes Inc., Deutsche Bank AG, Two Sigma Advisers LP, JPMorgan Chase & Co., and Squarepoint Ops LLC. Company insiders that have sold Crispr Therapeutics company stock in the last year include Lawrence Otto Klein, Pablo J Cagnoni, Rodger Novak, and Samarth Kulkarni. View insider buying and selling activity for Crispr Therapeutics. Which institutional investors are buying Crispr Therapeutics stock? CRSP stock was purchased by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Morgan Stanley, Morgan Stanley, TimesSquare Capital Management LLC, Casdin Capital LLC, Capital International Investors, Bank of New York Mellon Corp, and Acadian Asset Management LLC. View insider buying and selling activity for Crispr Therapeutics. How do I buy shares of Crispr Therapeutics? Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Crispr Therapeutics' stock price today? One share of CRSP stock can currently be purchased for approximately $66.59. How big of a company is Crispr Therapeutics? Crispr Therapeutics has a market capitalization of $4.06 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis. Crispr Therapeutics employs 188 workers across the globe. What is Crispr Therapeutics' official website? The official website for Crispr Therapeutics is www.crisprtx.com. How can I contact Crispr Therapeutics? Crispr Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected] This page was last updated on 6/1/2020 by MarketBeat.com Staff
